Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D. Saloustros E, et al. Among authors: kentepozidis n. Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16. Breast Cancer Res Treat. 2014. PMID: 25399229 Clinical Trial.
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A. Souglakos J, et al. Among authors: kentepozidis n. Br J Cancer. 2012 Jan 31;106(3):453-9. doi: 10.1038/bjc.2011.594. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240792 Free PMC article. Clinical Trial.
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V. Katopodis O, et al. Among authors: kentepozidis n. Cancer Chemother Pharmacol. 2014 Aug;74(2):333-40. doi: 10.1007/s00280-014-2509-6. Epub 2014 Jun 15. Cancer Chemother Pharmacol. 2014. PMID: 24930058 Clinical Trial.
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. Kontopodis E, et al. Among authors: kentepozidis n. Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15. Cancer Chemother Pharmacol. 2015. PMID: 25398698 Clinical Trial.
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. Kotsakis A, et al. Among authors: kentepozidis n. Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23. Lung Cancer. 2015. PMID: 25662596 Clinical Trial.
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece. Mavroudis D, et al. Among authors: kentepozidis n. Ann Oncol. 2015 Jul;26(7):1333-40. doi: 10.1093/annonc/mdv213. Epub 2015 May 1. Ann Oncol. 2015. PMID: 25935793 Free article. Clinical Trial.
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece. Mavroudis D, et al. Among authors: kentepozidis n. Ann Oncol. 2016 Oct;27(10):1873-8. doi: 10.1093/annonc/mdw274. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502729 Free article. Clinical Trial.
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: kentepozidis n. Ann Oncol. 2019 Aug 1;30(8):1304-1310. doi: 10.1093/annonc/mdz193. Ann Oncol. 2019. PMID: 31228203 Free article.
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, Mavroudis D, Georgoulias V. Boukovinas I, et al. Among authors: kentepozidis n. Cancer Chemother Pharmacol. 2012 Feb;69(2):351-6. doi: 10.1007/s00280-011-1694-9. Epub 2011 Jul 12. Cancer Chemother Pharmacol. 2012. PMID: 21748359 Clinical Trial.
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V. Mavroudis D, et al. Among authors: kentepozidis n. Br J Cancer. 2017 Jul 11;117(2):164-170. doi: 10.1038/bjc.2017.158. Epub 2017 Jun 22. Br J Cancer. 2017. PMID: 28641315 Free PMC article. Clinical Trial.
75 results